# Longitudinal PET Imaging of Antipsychotic Binding to the Dopamine-3 Receptor in Schizophrenia

> **NCT07715253** · PHASE1 · NOT_YET_RECRUITING · sponsor: **New York State Psychiatric Institute** · enrollment: 100 (estimated)

## Conditions studied

- Schizoaffective Disorder
- Schizophreniform Disorder
- Schizophrenia

## Interventions

- **DRUG:** Brexpiprazole
- **DRUG:** Cariprazine
- **DRUG:** [11C] PHNO

## Key facts

- **NCT ID:** NCT07715253
- **Lead sponsor:** New York State Psychiatric Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-12-01
- **Primary completion:** 2030-08-30
- **Final completion:** 2030-11-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-07-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07715253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07715253, "Longitudinal PET Imaging of Antipsychotic Binding to the Dopamine-3 Receptor in Schizophrenia". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07715253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*